Klaeschen Anna Sophie, Wolf Dominik, Brossart Peter, Bieber Thomas, Wenzel Joerg
Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany.
Medical Clinic III, Hematology, Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany.
Exp Dermatol. 2017 Aug;26(8):728-730. doi: 10.1111/exd.13253. Epub 2017 May 3.
This study was stimulated by the clinical observation of a rapid response of a chilblain lupus patient to treatment with JAK1/2-kinase inhibitor ruxolitinib. We investigated the in vivo expression of phospho-JAK2 in CLE skin samples as well as the immunomodulatory in vitro effect of ruxolitinib in cultured immortalized keratinocytes and in a 3D human epidermis model (epiCS). Our results demonstrate that ruxolitinib significantly decreases the production of CLE-typical cytokines (CXCL10, CXCL9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.
本研究受冻疮样狼疮患者对JAK1/2激酶抑制剂鲁索替尼治疗产生快速反应的临床观察启发。我们研究了CLE皮肤样本中磷酸化JAK2的体内表达，以及鲁索替尼在培养的永生化角质形成细胞和三维人表皮模型（epiCS）中的体外免疫调节作用。我们的结果表明，鲁索替尼显著降低了CLE典型细胞因子（CXCL10、CXCL9、Mx A）的产生，可能是未来用于CLE及相关自身免疫性皮肤病患者临床研究的一种有前景的药物。
